HK1186205A1 - Tricyclo-phosphorothioate dna dna - Google Patents
Tricyclo-phosphorothioate dna dnaInfo
- Publication number
- HK1186205A1 HK1186205A1 HK13111544.3A HK13111544A HK1186205A1 HK 1186205 A1 HK1186205 A1 HK 1186205A1 HK 13111544 A HK13111544 A HK 13111544A HK 1186205 A1 HK1186205 A1 HK 1186205A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- dna
- tricyclo
- phosphorothioate
- phosphorothioate dna
- dna dna
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/33—Alteration of splicing
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11185129.1A EP2581448B1 (en) | 2011-10-13 | 2011-10-13 | Tricyclo-phosphorothioate DNA |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1186205A1 true HK1186205A1 (en) | 2014-03-07 |
Family
ID=44799824
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK13111544.3A HK1186205A1 (en) | 2011-10-13 | 2013-10-15 | Tricyclo-phosphorothioate dna dna |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9738891B2 (xx) |
| EP (2) | EP2581448B1 (xx) |
| JP (1) | JP6181653B2 (xx) |
| CN (1) | CN104245935B (xx) |
| AU (1) | AU2012322903B2 (xx) |
| BR (1) | BR112014009066B8 (xx) |
| CA (2) | CA2776651C (xx) |
| DK (1) | DK2581448T3 (xx) |
| ES (2) | ES2535654T3 (xx) |
| HK (1) | HK1186205A1 (xx) |
| IL (1) | IL231983B (xx) |
| IN (1) | IN2014DN03463A (xx) |
| PL (1) | PL2581448T3 (xx) |
| PT (1) | PT2581448E (xx) |
| WO (1) | WO2013053928A1 (xx) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4047096A1 (en) | 2004-06-28 | 2022-08-24 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
| EP1855694B1 (en) | 2005-02-09 | 2020-12-02 | Sarepta Therapeutics, Inc. | Antisense composition for treating muscle atrophy |
| EP3428278A1 (en) | 2008-10-24 | 2019-01-16 | Sarepta Therapeutics, Inc. | Multiple exon skipping compositions for dmd |
| CN103003430A (zh) | 2009-11-12 | 2013-03-27 | 西澳大利亚大学 | 反义分子和治疗疾病的方法 |
| US20130085139A1 (en) | 2011-10-04 | 2013-04-04 | Royal Holloway And Bedford New College | Oligomers |
| EA202090946A3 (ru) | 2013-03-14 | 2021-07-30 | Сарепта Терапьютикс, Инк. | Композиции, обеспечивающие пропускание экзонов, для лечения мышечной дистрофии |
| NZ631289A (en) | 2013-03-15 | 2017-08-25 | Sarepta Therapeutics Inc | Improved compositions for treating muscular dystrophy |
| EP3041935A1 (en) | 2013-09-05 | 2016-07-13 | Sage Therapeutics, Inc. | Antisense-induced exon2 inclusion in acid alpha-glucosidase |
| DK3044315T3 (da) | 2013-09-11 | 2019-05-20 | Synthena Ag | Nukleinsyrer og fremgangsmåder til behandling af pompes sygdom |
| JP6872479B2 (ja) | 2014-07-31 | 2021-05-19 | アソシアシオン・アンスティテュ・ドゥ・ミオロジーＡｓｓｏｃｉａｔｉｏｎ Ｉｎｓｔｉｔｕｔ Ｄｅ Ｍｙｏｌｏｇｉｅ | 筋萎縮性側索硬化症の処置 |
| MA41795A (fr) | 2015-03-18 | 2018-01-23 | Sarepta Therapeutics Inc | Exclusion d'un exon induite par des composés antisens dans la myostatine |
| EP3851531A1 (en) | 2015-06-01 | 2021-07-21 | Sarepta Therapeutics, Inc. | Antisense-induced exon exclusion in type vii collagen |
| CA2999192A1 (en) | 2015-09-21 | 2017-03-30 | Association Institut De Myologie | Antisense oligonucleotides hybridizing with a key element of the polyadenylation region of a dux4 pre-mrna and uses thereof |
| EP3359668A4 (en) | 2015-10-09 | 2019-06-05 | Sarepta Therapeutics, Inc. | COMPOSITIONS AND METHODS OF TREATING DUCHENNE MUSCLE DYSTROPHY AND ASSOCIATED ILLNESSES THEREOF |
| WO2017136435A1 (en) | 2016-02-01 | 2017-08-10 | The Usa, As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer National Institute Of Health | Compounds for modulating fc-epsilon-ri-beta expression and uses thereof |
| WO2017184529A1 (en) | 2016-04-18 | 2017-10-26 | Sarepta Therapeutics, Inc. | Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene |
| NZ747685A (en) | 2016-04-29 | 2023-05-26 | Sarepta Therapeutics Inc | Oligonucleotide analogues targeting human lmna |
| MA45362A (fr) | 2016-05-24 | 2019-04-10 | Sarepta Therapeutics Inc | Procédés de préparation d'oligomères morpholino de phosphorodiamidate |
| CN109311920B (zh) | 2016-05-24 | 2021-11-09 | 萨勒普塔医疗公司 | 制备磷酸二酰胺吗啉代寡聚物的方法 |
| US11472824B2 (en) | 2016-05-24 | 2022-10-18 | Sarepta Therapeutics, Inc. | Processes for preparing phosphorodiamidate morpholino oligomers |
| US10875880B2 (en) | 2016-05-24 | 2020-12-29 | Sarepta Therapeutics, Inc. | Processes for preparing oligomers |
| WO2018005805A1 (en) | 2016-06-30 | 2018-01-04 | Sarepta Therapeutics, Inc. | Exon skipping oligomers for muscular dystrophy |
| WO2018055577A1 (en) * | 2016-09-23 | 2018-03-29 | Synthena Ag | Mixed tricyclo-dna, 2'-modified rna oligonucleotide compositions and uses thereof |
| EP3516061A1 (en) | 2016-09-23 | 2019-07-31 | Synthena AG | Mixed tricyclo-dna, 2'-modified rna oligonucleotide compositions and uses thereof |
| LT3554554T (lt) | 2016-12-19 | 2022-11-25 | Sarepta Therapeutics, Inc. | Egzoną praleidžiantys oligomero konjugatai nuo raumenų distrofijos |
| WO2018118599A1 (en) | 2016-12-19 | 2018-06-28 | Sarepta Therapeutics, Inc. | Exon skipping oligomer conjugates for muscular dystrophy |
| CA3047010A1 (en) | 2016-12-19 | 2018-06-28 | Sarepta Therapeutics, Inc. | Exon skipping oligomer conjugates for muscular dystrophy |
| CA3060514A1 (en) | 2017-04-20 | 2018-10-25 | Atyr Pharma, Inc. | Compositions and methods for treating lung inflammation |
| KR20190141184A (ko) * | 2017-04-20 | 2019-12-23 | 신테나 아게 | 트리시클로-dna 뉴클레오시드를 포함하는 변형 올리고머 화합물 및 그의 용도 |
| WO2018193428A1 (en) | 2017-04-20 | 2018-10-25 | Synthena Ag | Modified oligomeric compounds comprising tricyclo-dna nucleosides and uses thereof |
| EA201991450A1 (ru) | 2017-09-22 | 2019-12-30 | Сарепта Терапьютикс, Инк. | Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии |
| JP2020536060A (ja) | 2017-09-28 | 2020-12-10 | サレプタ セラピューティクス， インコーポレイテッド | 筋ジストロフィーを処置するための併用療法 |
| WO2019067979A1 (en) | 2017-09-28 | 2019-04-04 | Sarepta Therapeutics, Inc. | POLYTHERAPIES FOR TREATING MUSCLE DYSTROPHY |
| US20210145852A1 (en) | 2017-09-28 | 2021-05-20 | Sarepta Therapeutics, Inc. | Combination Therapies for Treating Muscular Dystrophy |
| WO2019079637A2 (en) | 2017-10-18 | 2019-04-25 | Sarepta Therapeutics, Inc. | ANTISENSE OLIGOMERIC COMPOUNDS |
| US10758629B2 (en) | 2018-05-29 | 2020-09-01 | Sarepta Therapeutics, Inc. | Exon skipping oligomer conjugates for muscular dystrophy |
| EP3806868A4 (en) | 2018-06-13 | 2022-06-22 | Sarepta Therapeutics, Inc. | EXON-SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHY |
| TW202020153A (zh) | 2018-07-27 | 2020-06-01 | 美商薩羅塔治療公司 | 用於肌肉萎縮症之外顯子跳躍寡聚物 |
| BR112021011018A2 (pt) | 2018-12-13 | 2021-08-31 | Sarepta Therapeutics, Inc. | Conjugados de oligômero para exon skipping para distrofia muscular |
| EP3955966A1 (en) | 2019-04-18 | 2022-02-23 | Sarepta Therapeutics, Inc. | Compositions for treating muscular dystrophy |
| JP2023500884A (ja) | 2019-11-06 | 2023-01-11 | アソシエーション・アンスティトゥート・ドゥ・マイオロジー | 筋疾患のための併用療法 |
| BR112022016238A2 (pt) | 2020-02-28 | 2022-10-11 | Ionis Pharmaceuticals Inc | Compostos e métodos para modular smn2 |
| US20230139408A1 (en) | 2020-04-09 | 2023-05-04 | Association Institut De Myologie | Antisense sequences for treating amyotrophic lateral sclerosis |
| EP3978608A1 (en) | 2020-10-05 | 2022-04-06 | SQY Therapeutics | Oligomeric compound for dystrophin rescue in dmd patients throughout skipping of exon-51 |
| WO2023055774A1 (en) | 2021-09-30 | 2023-04-06 | Sarepta Therapeutics, Inc. | Antisense oligonucleotides having one or more abasic units |
| WO2023070086A1 (en) | 2021-10-22 | 2023-04-27 | Sarepta Therapeutics, Inc. | Morpholino oligomers for treatment of peripheral myelin protein 22 related diseases |
| WO2024064237A2 (en) | 2022-09-21 | 2024-03-28 | Sarepta Therapeutics, Inc. | Dmd antisense oligonucleotide-mediated exon skipping efficiency |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5820873A (en) | 1994-09-30 | 1998-10-13 | The University Of British Columbia | Polyethylene glycol modified ceramide lipids and liposome uses thereof |
| US5753613A (en) | 1994-09-30 | 1998-05-19 | Inex Pharmaceuticals Corporation | Compositions for the introduction of polyanionic materials into cells |
| US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
| AU1922999A (en) | 1997-12-16 | 1999-07-05 | Baylor College Of Medicine | Needle-free injection of formulated nucleic acid molecules |
| MXPA01009073A (es) | 1999-03-10 | 2002-05-06 | Phogen Ltd | Suministro de acidos nucleicos y proteinas a las celulas. |
| NZ542687A (en) | 2003-04-13 | 2010-02-26 | Enzon Pharmaceuticals Inc | Polymeric oligonucleotide prodrugs |
| WO2007073149A1 (en) * | 2005-12-22 | 2007-06-28 | Keygene N.V. | Alternative nucleotides for improved targeted nucleotide exchange |
| AU2007296054B2 (en) * | 2006-09-15 | 2013-03-28 | Enzon Pharmaceuticals, Inc. | Hindered ester-based biodegradable linkers for oligonucleotide delivery |
| US20100016215A1 (en) * | 2007-06-29 | 2010-01-21 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| ES2694726T3 (es) * | 2007-06-29 | 2018-12-26 | Sarepta Therapeutics, Inc. | Conjugados peptídicos específicos de tejido y métodos |
| TW201023914A (en) * | 2008-11-17 | 2010-07-01 | Enzon Pharmaceuticals Inc | Releasable polymeric lipids for nucleic acids delivery system |
| CA2758189C (en) * | 2009-04-10 | 2020-12-29 | Association Institut De Myologie | Tricyclo-dna antisense oligonucleotides, compositions, and methods for the treatment of disease |
| US20140022812A1 (en) | 2011-02-25 | 2014-01-23 | Lumitex, Inc. | Display front lighting device |
-
2011
- 2011-10-13 ES ES11185129.1T patent/ES2535654T3/es active Active
- 2011-10-13 PL PL11185129T patent/PL2581448T3/pl unknown
- 2011-10-13 EP EP11185129.1A patent/EP2581448B1/en active Active
- 2011-10-13 PT PT111851291T patent/PT2581448E/pt unknown
- 2011-10-13 DK DK11185129T patent/DK2581448T3/en active
-
2012
- 2012-04-27 CA CA2776651A patent/CA2776651C/en active Active
- 2012-10-12 BR BR112014009066A patent/BR112014009066B8/pt active IP Right Grant
- 2012-10-12 CN CN201280057688.6A patent/CN104245935B/zh active Active
- 2012-10-12 WO PCT/EP2012/070349 patent/WO2013053928A1/en active Application Filing
- 2012-10-12 AU AU2012322903A patent/AU2012322903B2/en active Active
- 2012-10-12 EP EP12770503.6A patent/EP2766479B1/en active Active
- 2012-10-12 ES ES12770503.6T patent/ES2651216T3/es active Active
- 2012-10-12 US US14/351,733 patent/US9738891B2/en active Active
- 2012-10-12 CA CA2851970A patent/CA2851970A1/en not_active Abandoned
- 2012-10-12 JP JP2014535113A patent/JP6181653B2/ja active Active
-
2013
- 2013-10-15 HK HK13111544.3A patent/HK1186205A1/xx unknown
-
2014
- 2014-04-07 IL IL231983A patent/IL231983B/en active IP Right Grant
- 2014-04-30 IN IN3463DEN2014 patent/IN2014DN03463A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN104245935A (zh) | 2014-12-24 |
| IL231983A0 (en) | 2014-05-28 |
| AU2012322903A1 (en) | 2014-05-29 |
| BR112014009066B8 (pt) | 2021-02-23 |
| JP2015501144A (ja) | 2015-01-15 |
| BR112014009066A8 (pt) | 2018-01-09 |
| US9738891B2 (en) | 2017-08-22 |
| WO2013053928A1 (en) | 2013-04-18 |
| CN104245935B (zh) | 2018-05-08 |
| CA2776651A1 (en) | 2013-04-13 |
| BR112014009066B1 (pt) | 2020-08-25 |
| IN2014DN03463A (xx) | 2015-06-05 |
| EP2766479A1 (en) | 2014-08-20 |
| PL2581448T3 (pl) | 2015-08-31 |
| ES2651216T3 (es) | 2018-01-25 |
| PT2581448E (pt) | 2015-05-21 |
| JP6181653B2 (ja) | 2017-08-16 |
| CA2776651C (en) | 2021-06-08 |
| BR112014009066A2 (pt) | 2017-04-18 |
| DK2581448T3 (en) | 2015-04-27 |
| US20140296323A1 (en) | 2014-10-02 |
| ES2535654T3 (es) | 2015-05-13 |
| EP2581448B1 (en) | 2015-01-28 |
| IL231983B (en) | 2018-04-30 |
| AU2012322903B2 (en) | 2017-09-14 |
| CA2851970A1 (en) | 2013-04-18 |
| EP2766479B1 (en) | 2017-09-13 |
| EP2581448A1 (en) | 2013-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL231983A0 (en) | Dna containing tricyclo-phosphorothioate | |
| DK2922554T3 (en) | Terminalt modificeret rna | |
| EP2790561A4 (en) | DISHWASHER | |
| EP2715659A4 (en) | ABOUT FEED | |
| ZA201205891B (en) | Dna polymerases | |
| EP2729182A4 (en) | NUCLEIC COMPLEX | |
| EP2754063A4 (en) | EXTENSIBILITY OF THE SMB2 PROTOCOL | |
| EP2723631A4 (en) | QUADFOILER | |
| GB201118636D0 (en) | Nucleotide sequence | |
| EP2776444A4 (en) | dihydropteridinones | |
| AP2014007621A0 (en) | 2-Thiopyrimidinones | |
| GB201100282D0 (en) | Biological methods | |
| EP2695208A4 (en) | MICRO-THERMOCOUPLE | |
| HK1245104A1 (zh) | Dna疫苗 | |
| EP2700414A4 (en) | SELF-GELATINABLE NUCLEIC ACID | |
| EP2679138A4 (en) | Borescope | |
| EP2708561A4 (en) | BIO-PIN | |
| EP2684382A4 (en) | EARPHONES | |
| EP2698098A4 (en) | campimeter | |
| EP2694655A4 (en) | pavec | |
| EP2702929A4 (en) | campimeter | |
| GB201100001D0 (en) | TidySqueeze2 | |
| AU4540P (en) | BUNNAN Baloskion tetraphyllum | |
| AU5171P (en) | Sunparamiho Mandevilla xamabilis | |
| AU5031P (en) | BESYS Beschorneria yuccoides |